Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus, Séverine Vermeire, Stefan Schreiber, Timothy Ritter, Ronald Fogel, Rajiv Mehta, Sandeep Nijhawan, Radosław Kempiński, Rafał Filip, Ihor Hospodarskyy, Ursula Seidler, Frank Seibold, Ian L.P. Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng LiuChia Hsiang Hsueh, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, William J. Sandborn, Gerhard Rogler, Toshifumi Hibi, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science